Αποτελέσματα Αναζήτησης
27 Απρ 2021 · Compared with other subtypes, the median survival of patients with IgD type received traditional chemotherapy is generally less than 2 years. 4 Studies have shown that combined with autologous hematopoietic stem cell transplantation, the use of proteasome inhibitors, immunomodulatory agents could significantly improve the prognosis of patients ...
1 Σεπ 2022 · The median age of patients with IgD myeloma was 59 years (Figure 1), and 20% were 65 years or older at the time of diagnosis (Table 1). In this series, most patients with IgD myeloma (61%) had a performance status of 3 or more, and this was comparable to light chain only myeloma (60%).
20 Οκτ 2022 · Abstract. IgD multiple myeloma is uncommon. Patients generally present at a younger age and have shorter progression free and overall survivals (OSs). Its rarity has inhibited development of a specific risk stratification system or informed best treatment protocols.
20 Οκτ 2020 · Immunoglobulin D (IgD) myeloma is a rare isotype that comprises 1–2% of multiple myeloma (MM) patients [1, 2, 3], which has significantly inferior survival for a median overall survival (OS)...
Life expectancy (LE) and years of life lost (YLL) of all cancer patients with respect to the age-matched cancer-free population at specific time points after diagnosis (0, 1, 5, 10, and 15 years) by sex and age at diagnosis.
Patients with IgD MM have a short survival (Median survival=9months). The presenting features included: bone pain (75%), lymphadenopathy (16%), hepatomegaly (25%), splenomegaly (8%), associated AL amyloidosis (6%), renal impairment function (82%), infections (47%), hypercalcemia (37%) and anemia (93%).
IgD represents about 0.25% of the total serum immunoglobulins and has an M r of 185,000 and a half-life of 2.8 days (131), similar to that of IgE (162). Its synthesis rate is at least 10 times lower than that of IgA, IgM, and IgG.
